Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 02 2025
0mins
Source: Globenewswire
Public Offering Announcement: Cellectar Biosciences, Inc. has successfully closed an underwritten public offering, raising approximately $6.9 million to fund general corporate purposes and initiate a Phase 1b clinical study for its cancer treatment compound CLR 121125.
Offering Details: The offering included Class A and Class B Units, with each unit comprising shares of common stock and warrants, priced at $5.00 and $4.99999 respectively, and was managed by Ladenburg Thalmann & Co. Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
